Of course, patients will only use a product that they find pleasant to use, easy to use, especially, once a day use. Therefore, patient adherence is proven to increase better outcomes with increased efficacy and tolerability.Patients with acne desire clearance. Dermatology providers today have more options than ever to tailor treatment to each patient’s needs, in light of current best evidence regarding the pathogenesis and treatment of the disease. While no new chemical entities for topical delivery have revolutionized our approach to acne management, ongoing evolution in topical vehicle formulation is optimizing therapeutic benefit and the patient experience, leading to better clinical outcomes.Leon H. Kircik MDIcahn School of Medicine at Mount Sinai, NYIndiana School of Medicine, Indianapolis, INPhysicians Skin Care, PLLC, Louisville, KYDermResearch, PLLC, Louisville, KYSkin Sciences, PLLC, Louisville, KYDisclosureDr. Kircik has received compensation from JDD for his editorial work.AcknowledgmentThis research was supported by a grant from Aqua Pharmaceuticals LLC, Exton, PA 19341.
REFERENCES
- 1. Karimkhani C, Dellavalle RP, Coffeng LE et al. Global Skin Disease Morbidity and Mortality: An Update from the Global Burden of Disease Study 2013. JAMA Dermatol. 2017 May 1;153(5):406-412.
- Yentzer BA, Hick J, Reese EL, Uhas A, et al. Acne vulgaris in the United States: a descriptive epidemiology. Cutis. 2010 Aug;86(2):94-9.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945-73
- Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):15-24
